Escape from the lab! Six promising biotech start-up companies profiled at all-day symposium

Escape from the lab! Six promising biotech start-up companies profiled at all-day symposium

October 1, 2018

October 1, 2018


ASU’s many laboratories are seedbeds for an astonishing variety of new ideas. But the path from basic research to real-world applications can be complex, perilous and sometimes, bewildering.

Recently, an all-day seminar, hosted at the Biodesign Institute, explored an array of promising research that has escaped the confines of the lab. New spinout companies, based on pathbreaking research, are bringing exciting innovations in the life sciences to market.

The gathering was organized by the ASU Biotechnology Advisory Board, a consortium consisting of national and international industry leaders in the biotech domain. The board’s role is to explore opportunities for students in the various biomedical fields as well as gauge the impact of biotech research across ASU.

The biotechnology sector is a high stakes world, in which billions of dollars can be made or lost overnight and the landscape is littered with the bones of failed biotech ventures.  Company leaders must be nimble and ready to abandon strategies that don’t work while being ever mindful of the company’s vision, goals, and overall approach.

The promise of stratospheric profits, coupled with dreams of making significant contributions to human health and societal betterment have driven a gold rush in biotechnology. Currently, the number of biotech IPOs is exploding and the winners have been among the best-performing IPOs in the market. So much for the good news. The fact is, the rate of failure of tech startups in general is around 75 percent according to Fast Company Magazine and biotech start-ups face many challenges unique to the industry. 

Today, potential investors are often wary after some biotech companies received extravagant valuations, only to come crashing down. While a few flame out in spectacular public manner, (Theranos perhaps representing the most extreme and unsettling case), most die quieter deaths as a result of insufficient funding, errors in management or poor navigation of the enormous practical hurdles involved. Suffice to say the field is not for the faint of heart.

On the other hand, the best ideas hold a potential, unrivaled in the business world, to radically transform human health and improve the quality of life for millions of people around the world.

The seminar kicked off with a discussion moderated by Bert Jacobs, director, School of Life Sciences, ASU, entitled Targeting Educational Goals to Fit Industry. Next, Neal Woodbury, director and professor, School of Molecular Sciences, moderated a discussion on Bioindustry Challenges and Academia’s Response.

The afternoon session featured rapid-fire descriptions of six new biotech start-ups, as members of the local business community peppered the presenters with questions and suggestions for furthering the success of these ventures.

Seed funding for new start-ups and the ins and outs of venture capital investment were explored. Companies can be overfunded before maturity and this can pose risks just as underfunding of new projects. One challenge common to most biotech start-ups is presentation; how to package and offer up enough of the salient science to entice potential investors without overwhelming them in minutiae. Protection of sensitive intellectual property, especially for companies seeking to break into the vast markets in China, can also be a critical consideration.

Products and innovations that may carry lethal risks must undergo extravagant vetting relative to most other products entering the marketplace, creating a landscape of exceptional complexity and risk for biotech companies. Team members savvy in the byzantine world of regulatory law are often required assets for successful teams.

In the biotech universe, timing is everything. Decisions that can make or break startups include when to interest larger biotech or pharma conglomerates in licensing some of your technology or buying your company outright. An unusual blend of optimism, aggressive perseverance and practicality are among the essential ingredients. When is it appropriate to tackle roadblocks and when should companies cut their losses for a promising idea that faces too many setbacks? Success requires a perfect storm of pathbreaking science, societal need, strong leadership in a variety of areas and adequacy of funding.

NanoPin is a company founded in 2017 by Tony Hu, a researcher in the Biodesign Virginia G. Piper Center for Personalized Diagnostics. Their proprietary technology, described by NanoPin CEO Thomas Tombler, uses a nanoparticle-based platform, coupled with high throughput mass spectroscopy to detect and quantitate disease biomarkers in patient blood samples. Specifically, Nanopin addresses the urgent need for more accurate, cost-effective diagnostic tools for tuberculosis, a deadly disease estimated to affect some 10 million people worldwide and cause 1.7 million annual deaths. TB can be difficult to diagnose using conventional methods, particularly in children and “paucibacillary” cases in which the abundance of mycobacterium—causative agent of the disease—is very low. Speed is also a critical component. The current gold standard diagnostic can take six to eight weeks to yield a final result, as opposed to NanoPin’s rapid diagnostic. The versatile platform holds the promise for rapid diagnosis of a range of diseases. NanoPin recently received $2 million in seed funding to develop this diagnostic and monitoring platform for tuberculosis management.

Improved cancer treatment and prevention are the focus of Stephen Albert Johnston’s startup company Calviri. Johnston is currently the director for the Center for Innovations in Medicine (CIM) and a professor in the School of Life Sciences. The company presentation, delivered by Douglas Thamm, director of Clinical Programs, described the use of peptide array technology to screen for cancer. Existing methods for analyzing tumor diversity in sequence data can take months. Further, the radical heterogeneity of many mutations found in cancerous tumors require time-consuming and exorbitant personalized therapies or vaccine designs. Calviri’s technology focuses on net-antigens, mutations that may be common to a broader range of cancer cases than the so-called neo-antigens that have been studied by the cancer community. By contrast, net antigens are produced through transcription and RNA splicing, producing highly immunogenic errors. Use of such net-antigens could enable faster, simpler, and less expensive methods for the production of personal cancer vaccines and perhaps one day, even a generally used cancer vaccine.  ASU was awarded $6.4M multi-year grant from the Open Philanthropy Project to test preventive cancer vaccines for dogs.

Grant McFadden, director of the Biodesign Center for Immunotherapy, Vaccines and Virotherapy (B-CIVV), presented details of his company OncoMyx Therapeutics. The spinout has leveraged McFadden’s research in virology to develop technologies targeting hematologic and solid tumors with a unique oncolytic virus called myxoma (MYXV) and a novel patented systemic delivery approach. Myxoma is a standout in the viral world, a pathogen found exclusively in rabbits, where its presence is rapidly lethal. The company however is interested in another property of myxoma, its effectiveness as an oncolytic or anti-cancer agent in humans. Myxoma, a member of the pox virus family, is highly immunostimulatory, and is non-pathogenic in any organism outside of rabbits. The virus has a unique ability to be carried systemically by human leukocytes where it can then infect tumor cells. OncoMyx will spearhead the next-stage development plans of oncolytic myxoma virus to seek FDA approval and conduct the first human clinical trials, using their patented systemic delivery approach. The company will capitalize on McFadden’s two decades of research into the potential of oncolytic viruses. Professor McFadden sequenced the myxoma virus genome in 1999, and since then has produced dozens of genetically engineered constructs, demonstrating its ability as an oncolytic agent across many tumors in preclinical cell and animal models.

FlexBioTech, Inc is another cancer-focused biotech startup co-founded by CEO physician scientist Karen Anderson, a researcher in the Biodesign Virginia G. Piper Center for  Personalized Diagnostics. In addition to her role as a translational cancer researcher at Biodesign, Anderson holds a joint appointment as a breast cancer medical oncologist at Mayo Clinic Arizona and professor in the School of Life Sciences, focused on tumor immunology, vaccine development, and biomarker development. She has developed clinical immune biomarkers for clinical use (Videssa Breast, Provista Diagnostics) and in clinical trials (HPV biomarkers, used in the HOUSTON trial at MD Anderson Cancer Center), and point of care diagnostics (in development for cervical cancer detection in India). FlexBioTech focuses on point of care biomarker detection. The technology permits rapid, low-cost home biomarker detection on a mobile platform that transmits results to hospitals and physicians.

Joseph Blattman is an immunologist who studies how the immune system responds to vaccination and viral infection.  He is a researcher in the Biodesign Center for Immunotherapy, Vaccines and Virotherapy. Blattman’s company, known as Gemneo Bioscience, is the 100th spinout company formed at ASU. Gemneo’s mission is to provide physicians with more optimal cancer treatments and groundbreaking immunotherapies to help improve cancer outcomes. The company is developing innovative molecular-based single-cell genomics technology that does not require cell sorting, which will greatly accelerate the speed and decrease the costs of analyzing the genomic heterogeneity of cancer and immune tissues, microbiomes, and beyond. Gemneo’s hopes to rapidly put their technology in the hands of academic and pharma industry researchers, to advance the frontiers of precision medicine, reduce costs, and improve patient outcomes. The research on DNA Origami Nanoprobes for single-cell multi-gene analysis and single-cell analysis of tumor heterogeneity was funded by NIH grants and is an excellent example of federally-funded research leading to advances in science and medicine. Gemneo’s platform technology can be used to profile cancer genomics and identify rare cells that influence disease progression that current technologies are not able to detect.

The burgeoning field of aging research has given rise to Wayne Frasch’s startup biotech company, Attometrics, which has developed technologies for evaluating telomere length. Telomeres—structures adorning the ends of chromosomes, have been implicated in not only the aging process but as signposts of disease. Certain cancer cells for example display unusually long telomeres believed to be linked with these cells’ status as immortal entities engaged in unchecked replication, one of the hallmarks of cancer. Telomeres therefore may provide an intriguing and powerful new tool for cancer diagnosis. Attometrics technology can quickly and accurately compute the length of telomeres at the ends of human chromosomes. Due to the strong correlation between telomere length and many age-related diseases and cancers, there has been an urgent need to develop a reproducible telomere length assay. Frasch, a researcher at ASU’s School of Life Sciences, is a pioneer in single-molecule nanotechnology, using this knowledge to create molecular motor-powered nanodevices (MONAs) that serve as a platform technology capable of quickly detecting target biomarkers for disease that are present in extremely low amounts.   

All of the participants received lively feedback from business experts during seminar discussions, helping to bring their visions to life and improve the chances for company success in a demanding but uniquely rewarding business landscape. 


Written by: Richard Harth